Ann: First-in-human Study Progress Update, page-104

If you read a bit further down the page

"As it is the first clinical investigation of the Company’s MagSense® technology the study was designed to be a small proof-of-principle study with the primary objective of achieving an initial assessment of the safety and tolerability of the MagSense ® injectable imaging agent. A secondary objective of the study is the confirmation that the route of administration is effective in allowing the imaging agent to reach the patient’s lymph nodes.

Each patient in the study receives an injection of the MagSense ® HER2 targeted imaging agent and evaluation by two imaging modalities: magnetic resonance imaging (MRI) and our proprietary magnetic relaxometry (MRX) technology. The exploratory objectives of the study include a comparison of the MRI and MRX results to standard clinical tissue histopathology to achieve a preliminary assessment as to whether the MagSense ® HER2 imaging agent when used with one or both imaging modalities might be able to provide a non-invasive alternative to nodal biopsy. The study intends to enrol approximately 15 patients,allowing the Company to assess preliminary clinical investigative questions before committing to larger enabling studies"